Weight loss & GLP-1 cost, clearly.

We bill your visits to your insurance whenever they are covered, so your out-of-pocket is your plan's copay or deductible amount. If your visits are not covered, our self-pay rates are $200 for the initial consultation and $100 for each follow-up, billed separately from the medication. On the medication side, when insurance covers it you typically pay a copay; when it doesn't, branded Wegovy (semaglutide) is available through the NovoCare program from $349/mo and tirzepatide via Lilly Direct is $299 to $449/mo depending on dose. Pricing is clear and all-in with no surprise fees, and we verify your coverage before you start.

Coverage varies widely. Commercial plans may cover FDA-approved weight-loss medication, usually with prior authorization, and many exclude it entirely. Medicare changed in 2026: from 1 July 2026 through 31 December 2027, CMS is running a demonstration called the Medicare GLP-1 Bridge, which gives eligible Part D beneficiaries certain weight-management GLP-1s for a $50 monthly copay. It currently covers all formulations of Wegovy and Foundayo and the Zepbound KwikPen. Eligibility is specific (a BMI of 35 or higher, or 30 or higher with heart failure, uncontrolled high blood pressure or stage 3a-plus kidney disease, or 27 or higher with pre-diabetes, a prior heart attack or stroke, or symptomatic peripheral artery disease), and the Bridge sits outside the ordinary Part D benefit, so your Part D plan does not have to opt in for you to use it. Separately, regular Part D may still cover these medicines when they are prescribed for another approved use, such as Zepbound for obstructive sleep apnea or Wegovy for cardiovascular risk reduction. Our team works out which pathway applies to your plan and your diagnosis before you start. We handle the prior-authorization paperwork either way.

Our program is built to include the things that actually drive results: your medical evaluation, follow-up visits, dose titration, side-effect management, and nutrition coaching. Visits are billed to insurance where covered. If they are not covered, self-pay is $200 for the initial consultation and $100 per follow-up. The medication itself is billed separately, through your pharmacy and insurance or self-pay.

You have options. If your visits are not covered, our self-pay rates are $200 for the initial consultation and $100 per follow-up, and we offer financing through Cherry, and we can use HSA/FSA dollars where eligible. We also help you explore manufacturer savings programs for branded medications. We do not substitute compounded GLP-1 as a cheaper workaround.

No. Omnia Health prescribes only FDA-approved, branded GLP-1 medications. We do not offer compounded semaglutide or tirzepatide, even though they can be cheaper. Compounded versions are not FDA-evaluated for safety, quality, or effectiveness, and we won't cut that corner.

Yes. For patients without coverage, we offer financing through Cherry, and HSA/FSA funds can be applied where eligible. Our goal is a transparent, predictable cost, no hidden or surprise fees.